The Hong Kong patent application forms part of Clearmind’s exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem ("Yissum"). Under the terms of the licensing agreement, Clearmind holds exclusive global rights to develop, manufacture, and commercialize novel compounds developed at Yissum. Clearmind is responsible for advancing the development program in accordance with regulatory requirements.

According to recent market reports, the global PTSDtreatment market is valued at approximately USD 18.5 billion in 2025 and is projected to reach USD 30.2 billion by 2035, growing at a CAGR of 5.0%.

This filing further strengthens Clearmind’s position as an innovator with a rapidly expanding global IP portfolio. Clearmind believes the Asian market- represents a major commercial opportunity, and securing patent protection in Hong Kong provides a strategic gateway for regional market access. This filingenhances Clearmind’s established patent coverage in the United States, Europe, and other key jurisdictions and reinforcing the Company’s long-term value creation strategy.